Regencell Bioscience Holdings Ltd
RGC · XNASCIK 1829667fmd_1FP9A7Z4QSVT7T6VM4JX410AYWManufacturing · Medicinal Chemicals & Botanical ProductsTemplate: Standard
Coverage: Jul 01, 2018 to Jun 30, 2026, 8 periods
Latest annual · FY2026
Millions- Operating income
- (12)
- Net income
- (12)
- Free cash flow
- (3)
Daily close · RGCIEX trades only
Nov 09, 2026 to Nov 11, 2026 · 3 sessions5.45 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Key stats
Open AnalysisCompound annual growth
- Net income, 5 yearsFY2021 to FY2026
- n/m
Regencell Bioscience Holdings Ltd (RGC) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2026 | FY2025 | Change | Source |
|---|---|---|---|---|
| Operating income | -$11.7 million | -$3.8 million | 20-F 2026-10-07 · proof | |
| Net income | -$11.7 million | -$3.6 million | 20-F 2026-10-07 · proof | |
| Cash from operating activities | -$7.7 million | -$3.1 million | 20-F 2026-10-07 · proof | |
| Total assets | $14.7 million | $5.8 million | +155.9% | 20-F 2026-10-07 · proof |
| Total liabilities | $1.4 million | $895,308 | +54.2% | 20-F 2026-10-07 · proof |
| Cash and cash equivalents | $14.2 million | $2.4 million | +486.7% | 20-F 2026-10-07 · proof |
- What was Regencell Bioscience Holdings Ltd (RGC)'s operating income in fiscal 2026?
- Regencell Bioscience Holdings Ltd (RGC) reported operating income of -$11.7 million for fiscal 2026 (the year ended Jun 30, 2026), against -$3.8 million the year before. Source: the 20-F filed with the SEC on Oct 7, 2026. SEC
- What was Regencell Bioscience Holdings Ltd (RGC)'s net income in fiscal 2026?
- Regencell Bioscience Holdings Ltd (RGC) reported net income of -$11.7 million for fiscal 2026 (the year ended Jun 30, 2026), against -$3.6 million the year before. Source: the 20-F filed with the SEC on Oct 7, 2026. SEC
- What was Regencell Bioscience Holdings Ltd (RGC)'s cash from operating activities in fiscal 2026?
- Regencell Bioscience Holdings Ltd (RGC) reported cash from operating activities of -$7.7 million for fiscal 2026 (the year ended Jun 30, 2026), against -$3.1 million the year before. Source: the 20-F filed with the SEC on Oct 7, 2026. SEC
- What are Regencell Bioscience Holdings Ltd (RGC)'s total assets?
- As of Jun 30, 2026, Regencell Bioscience Holdings Ltd (RGC) reported total assets of $14.7 million, against $5.8 million a year earlier (+155.9%). Source: the 20-F filed with the SEC on Oct 7, 2026. SEC
- What are Regencell Bioscience Holdings Ltd (RGC)'s total liabilities?
- As of Jun 30, 2026, Regencell Bioscience Holdings Ltd (RGC) reported total liabilities of $1.4 million, against $895,308 a year earlier (+54.2%). Source: the 20-F filed with the SEC on Oct 7, 2026. SEC
- What are Regencell Bioscience Holdings Ltd (RGC)'s cash and cash equivalents?
- As of Jun 30, 2026, Regencell Bioscience Holdings Ltd (RGC) reported cash and cash equivalents of $14.2 million, against $2.4 million a year earlier (+486.7%). Source: the 20-F filed with the SEC on Oct 7, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:RGC&period_type=annual&limit=5"Information only, not investment advice.